半乳糖凝集素在静脉血栓形成中起作用吗？一篇综述。
Do galectins play a role in venous thrombosis? a review.
机构信息
Department of Surgery, University of Michigan, Jobst Vascular Research Laboratories, Section of Vascular Surgery, Cardiovascular Center, Ann Arbor, MI, USA.
出版信息
Thromb Res. 2010 May;125(5):373-6. doi: 10.1016/j.thromres.2009.11.011. Epub 2009 Dec 2.
Abstract
Galectins are a family of carbohydrate-binding proteins that have a high affinity to galactosides on cell surfaces and extra cellular glycoproteins. They are involved in a variety of biological functions, including modulation of cell apoptosis, cell activation and inflammation. Our laboratory has recently identified galectin-3 binding protein (Gal-3BP) as being up-regulated in a microparticle proteomics analysis for deep venous thrombosis (DVT) patients compared to negative controls. P-selectin, another glycoprotein involved in thrombus propagation, has proven a promising target for DVT management and has been widely studied by our group. Galectins are involved in P-selectin expression and can potentially be implicated in the venous thrombogenesis process. The function of galectins, their role in inflammation and thrombosis as well as their potential implications as a new pharmacological target for DVT management are reviewed in this manuscript.
摘要
半乳糖凝集素是一类具有高亲和力与细胞表面半乳糖苷和细胞外糖蛋白结合的糖结合蛋白。它们参与多种生物学功能，包括调节细胞凋亡、细胞激活和炎症。我们实验室最近在深静脉血栓形成（DVT）患者与阴性对照的微粒蛋白组学分析中发现半乳糖凝集素-3 结合蛋白（Gal-3BP）上调。参与血栓传播的另一种糖蛋白 P-选择素已被证明是 DVT 管理的有前途的靶点，并且已被我们小组广泛研究。半乳糖凝集素参与 P-选择素的表达，并且可能参与静脉血栓形成过程。本文综述了半乳糖凝集素的功能、它们在炎症和血栓形成中的作用以及它们作为 DVT 管理新的药理学靶点的潜在意义。
相似文献
1
Do galectins play a role in venous thrombosis? a review.半乳糖凝集素在静脉血栓形成中起作用吗？一篇综述。
Thromb Res. 2010 May;125(5):373-6. doi: 10.1016/j.thromres.2009.11.011. Epub 2009 Dec 2.
2
[Galectins in hematological malignancies--role, functions and potential therapeutic targets].[半乳糖凝集素在血液系统恶性肿瘤中的作用、功能及潜在治疗靶点]
Postepy Hig Med Dosw (Online). 2016 Feb 14;70:95-103. doi: 10.5604/17322693.1194808.
3
Evaluation of Plasma Concentrations of Galectins-1, 2 and 12 in Psoriasis and Their Clinical Implications.评估银屑病患者中半乳糖凝集素-1、2 和 12 的血浆浓度及其临床意义。
Biomolecules. 2023 Sep 30;13(10):1472. doi: 10.3390/biom13101472.
4
Male mice have increased thrombotic potential: sex differences in a mouse model of venous thrombosis.雄性小鼠具有增加的血栓形成倾向：静脉血栓形成小鼠模型中的性别差异。
Thromb Res. 2011 May;127(5):478-86. doi: 10.1016/j.thromres.2011.01.004. Epub 2011 Feb 5.
5
A model of in vivo human venous thrombosis that confirms changes in the release of specific soluble cell adhesion molecules in experimental venous thrombogenesis.
J Vasc Surg. 1999 Jul;30(1):139-47. doi: 10.1016/s0741-5214(99)70186-2.
6
Therapeutic Potential of Galectin-1 and Galectin-3 in Autoimmune Diseases.半乳糖凝集素-1 和半乳糖凝集素-3 在自身免疫性疾病中的治疗潜力。
Curr Pharm Des. 2022;28(1):36-45. doi: 10.2174/1381612827666210927164935.
7
Integrating structure and function of 'tandem-repeat' galectins.“串联重复”半乳糖凝集素的结构与功能整合
Front Biosci (Schol Ed). 2012 Jan 1;4(3):864-87. doi: 10.2741/s305.
8
Oligosaccharide specificity of galectins: a search by frontal affinity chromatography.半乳糖凝集素的寡糖特异性：通过前沿亲和色谱法进行的研究
Biochim Biophys Acta. 2002 Sep 19;1572(2-3):232-54. doi: 10.1016/s0304-4165(02)00311-2.
9
A new way to treat proximal deep venous thrombosis using E-selectin inhibition.使用 E-选择素抑制治疗近端深静脉血栓形成的新方法。
J Vasc Surg Venous Lymphat Disord. 2020 Mar;8(2):268-278. doi: 10.1016/j.jvsv.2019.08.016.
10
Galectins in apoptosis.半乳糖凝集素与细胞凋亡
Methods Enzymol. 2006;417:256-73. doi: 10.1016/S0076-6879(06)17018-4.
引用本文的文献
1
Prevalence and risk factors for asymptomatic venous thromboembolism in patients with primary brain tumors.原发性脑肿瘤患者无症状静脉血栓栓塞的患病率及危险因素
iScience. 2025 Jul 1;28(8):113039. doi: 10.1016/j.isci.2025.113039. eCollection 2025 Aug 15.
2
Galectin-3-binding protein and future venous thromboembolism.半乳糖凝集素-3结合蛋白与未来静脉血栓栓塞症
Res Pract Thromb Haemost. 2024 Jan 3;8(1):102311. doi: 10.1016/j.rpth.2023.102311. eCollection 2024 Jan.
3
Non-coding RNAs regulating endothelial progenitor cells for venous thrombosis: promising therapy and innovation.非编码 RNA 调控内皮祖细胞治疗静脉血栓形成：有前途的治疗方法和创新。
Stem Cell Res Ther. 2024 Jan 2;15(1):7. doi: 10.1186/s13287-023-03621-z.
4
Galectin functions in cancer-associated inflammation and thrombosis.半乳糖凝集素在癌症相关炎症和血栓形成中发挥作用。
Front Cardiovasc Med. 2023 Feb 17;10:1052959. doi: 10.3389/fcvm.2023.1052959. eCollection 2023.
5
Downregulation of miR-125a-5p Promotes Endothelial Progenitor Cell Migration and Angiogenesis and Alleviates Deep Vein Thrombosis in Mice Via Upregulation of MCL-1.miR-125a-5p 的下调通过上调 MCL-1 促进内皮祖细胞迁移和血管生成，并减轻小鼠深静脉血栓形成。
Mol Biotechnol. 2023 Oct;65(10):1664-1678. doi: 10.1007/s12033-023-00676-4. Epub 2023 Feb 4.
6
Depleted miR-125a-5p Causes Vascular Endothelial Cell Dysfunction in Deep Vein Thrombosis by Targeting Angiopoietin 2.miR-125a-5p缺失通过靶向血管生成素2导致深静脉血栓形成中的血管内皮细胞功能障碍。
Indian J Hematol Blood Transfus. 2023 Jan;39(1):116-122. doi: 10.1007/s12288-022-01572-8. Epub 2022 Sep 7.
7
An Inhaled Galectin-3 Inhibitor in COVID-19 Pneumonitis: A Phase Ib/IIa Randomized Controlled Clinical Trial (DEFINE).在 COVID-19 肺炎中吸入半乳糖凝集素-3 抑制剂：一项 Ib/IIa 期随机对照临床试验（DEFINE）。
Am J Respir Crit Care Med. 2023 Jan 15;207(2):138-149. doi: 10.1164/rccm.202203-0477OC.
8
Timing of Endovascular Interventions for Iliac Vein Compression Syndrome With Thrombus.髂静脉压迫综合征伴血栓的血管内介入治疗时机。
Clin Appl Thromb Hemost. 2021 Jan-Dec;27:10760296211026974. doi: 10.1177/10760296211026974.
9
Protein Composition of the Subretinal Fluid Suggests Selective Diffusion of Vitreous Proteins in Retinal Detachment.视网膜下液的蛋白质组成表明玻璃体蛋白质在视网膜脱离中存在选择性扩散。
Transl Vis Sci Technol. 2020 Oct 14;9(11):16. doi: 10.1167/tvst.9.11.16. eCollection 2020 Oct.
10
LncRNA GUSBP5-AS promotes EPC migration and angiogenesis and deep vein thrombosis resolution by regulating FGF2 and MMP2/9 through the miR-223-3p/FOXO1/Akt pathway.长链非编码 RNA GUSBP5-AS 通过 miR-223-3p/FOXO1/Akt 通路调控 FGF2 和 MMP2/9 促进 EPC 迁移和血管生成及深静脉血栓溶解。
Aging (Albany NY). 2020 Mar 10;12(5):4506-4526. doi: 10.18632/aging.102904.
本文引用的文献
1
Silencing of galectin-3 changes the gene expression and augments the sensitivity of gastric cancer cells to chemotherapeutic agents.沉默半乳糖凝集素-3改变基因表达并增强胃癌细胞对化疗药物的敏感性。
Cancer Sci. 2010 Jan;101(1):94-102. doi: 10.1111/j.1349-7006.2009.01364.x. Epub 2009 Sep 14.
2
Galectin-3 targeted therapy with a small molecule inhibitor activates apoptosis and enhances both chemosensitivity and radiosensitivity in papillary thyroid cancer.半乳糖凝集素-3 靶向治疗联合小分子抑制剂激活甲状腺乳头状癌细胞凋亡，增强其化疗敏感性和放疗敏感性。
Mol Cancer Res. 2009 Oct;7(10):1655-62. doi: 10.1158/1541-7786.MCR-09-0274. Epub 2009 Oct 13.
3
Galectin-3 increases gastric cancer cell motility by up-regulating fascin-1 expression.半乳糖凝集素-3 通过上调 fascin-1 的表达促进胃癌细胞的迁移。
Gastroenterology. 2010 Mar;138(3):1035-45.e1-2. doi: 10.1053/j.gastro.2009.09.061. Epub 2009 Oct 8.
4
The relationship between serum galectin-3 and serum markers of cardiac extracellular matrix turnover in heart failure patients.心力衰竭患者血清半乳糖凝集素-3与心脏细胞外基质周转血清标志物之间的关系。
Clin Chim Acta. 2009 Nov;409(1-2):96-9. doi: 10.1016/j.cca.2009.09.001. Epub 2009 Sep 10.
5
Synthetic galectin-3 inhibitor increases metastatic cancer cell sensitivity to taxol-induced apoptosis in vitro and in vivo.合成半乳糖凝集素-3抑制剂在体外和体内均可提高转移性癌细胞对紫杉醇诱导的细胞凋亡的敏感性。
Neoplasia. 2009 Sep;11(9):901-9. doi: 10.1593/neo.09594.
6
Evidence of heavy methylation in the galectin 3 promoter in early stages of prostate adenocarcinoma: development and validation of a methylated marker for early diagnosis of prostate cancer.前列腺腺癌早期半乳糖凝集素 3 启动子的高甲基化证据：用于前列腺癌早期诊断的甲基化标志物的开发和验证。
Transl Oncol. 2009 Aug 18;2(3):146-56. doi: 10.1593/tlo.09118.
7
Serum levels of galectin-3 and its ligand 90k/mac-2bp in colorectal cancer patients.血清半乳糖凝集素-3 及其配体 90k/mac-2bp 在结直肠癌患者中的水平。
Immunopharmacol Immunotoxicol. 2010 Mar;32(1):160-4. doi: 10.1080/08923970902936880.
8
Galectin-3: a novel mediator of heart failure development and progression.半乳糖凝集素-3：心力衰竭发生发展的新型介质。
Eur J Heart Fail. 2009 Sep;11(9):811-7. doi: 10.1093/eurjhf/hfp097. Epub 2009 Jul 31.
9
Newer biomarkers in heart failure.心力衰竭中的新型生物标志物
Heart Fail Clin. 2009 Oct;5(4):579-88. doi: 10.1016/j.hfc.2009.04.004.
10
Evaluation of the prognostic significance of serum galectin-3 in American Joint Committee on Cancer stage III and stage IV melanoma patients.评估血清半乳糖凝集素-3在 AJCC 分期 III 期和 IV 期黑色素瘤患者中的预后意义。
Melanoma Res. 2009 Oct;19(5):316-20. doi: 10.1097/CMR.0b013e32832ec001.
Zotero 插件